Article record

评估非地方性儿童鼻咽癌治疗前EB病毒水平的预后相关性

Evaluating the Prognostic Relevance of Pre-Treatment Epstein-Barr Virus Levels in Non-Endemic Pediatric Nasopharyngeal Carcinoma.

临床研究鼻咽癌IF 5.1Q2

文献信息

PMID	42738320
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Ahmed Farrag 查看其他 20 位作者 Yanbo Yang；Jin Piao；Lindsay Younis；Hans-Joachim Wagner；Hans Christiansen；Tristan Römer；Allison Poore；Christopher Szot；Nadia Thibeau；Sue S Yom；Benjamin A Pinsky；Quynh-Thu Le；Junne Kamihara；David T Ting；Theodore W Laetsch；Kenneth S Chen；Carlos Rodriguez-Galindo；Randall T Hayden；Udo Kontny；Robyn D Gartrell
作者单位	Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany. 查看其他 19 条单位信息 Center for Integrative Oncology Aachen Bonn Cologne Düsseldorf, 52074 Aachen, Germany.；Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut 71515, Egypt.；Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children's Hospital of Central Switzerland, 6004 Lucerne, Switzerland.；Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.；Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.；Children's Oncology Group, Monrovia, CA 91016, USA.；Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, 35392 Giessen, Germany.；Department of Radiotherapy and Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany.；Biospecimen Research Group, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.；Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, USA.；Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.；Department of Radiation Oncology, Stanford University, Stanford, CA 94304, USA.；Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02115, USA.；Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA 02129, USA.；Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.；Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390, USA.；Department of Oncology and Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.；Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.；Departments of Pediatrics and Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
期刊	Cancers
SCI 分区	Q2
IF	5.1
研究类型	临床研究 · 临床
所属专科	鼻咽癌

中文摘要

背景/目的： 儿童鼻咽癌（NPC）是一种非常罕见的儿童癌症，与EB病毒（EBV）感染密切相关。我们研究了来自两个大型研究中心——北美儿童肿瘤学组（COG）和欧洲德国儿童肿瘤学与血液学学会（GPOH）——的儿童NPC中EBV DNA对分期和结局的预后价值。方法：对2006年至2012年在COG研究ARAR0331中以及2003年至2021年在GPOH NPC方案中治疗的NPC患者所采集的样本进行回顾性分析，检测可获得的血浆EBV DNA（P-EBV）或全血EBV DNA（WB-EBV）水平，包括治疗前和诱导化疗后。根据治疗前EBV值的中位数将患者分为高值和低值两组。结果：评估了102例患者的治疗前EBV DNA水平（分别来自COG和GPOH的50例和23例P-EBV DNA，以及来自GPOH的29例WB-EBV）和61例患者的诱导后EBV DNA水平（分别来自COG和GPOH的31例和12例P-EBV DNA，以及来自GPOH的18例WB-EBV DNA）。在任何队列中，患者特征（包括年龄和疾病分期）均与高和低P-EBV值无关。在GPOH WB-EBV队列中，疾病分期与高EBV水平相关（p = 0.014）。治疗前P-EBV和WB-EBV水平与5年无事件生存率（EFS：COG p = 0.65，GPOH P-EBV：p = 0.08，GPOH WB-EBV：p = 0.75）或5年总生存率（OS：COG p = 0.90，GPOH P-EBV p = 0.17，GPOH WB-EBV p = 0.19）均无显著关联。结论：我们的研究未能确立非地方性地区儿童NPC患者治疗前EBV DNA与结局之间的显著相关性。

英文摘要

Background/Objectives: Pediatric nasopharyngeal carcinoma (NPC) is a very rare childhood cancer strongly associated with Epstein-Barr virus (EBV) infection. We investigated the prognostic value of EBV DNA on staging and outcome in pediatric NPC from two large study centers, the Children's Oncology Group (COG) in North America and the German Society of Pediatric Oncology and Hematology (GPOH) in Europe. Methods: Samples collected from NPC patients treated on the COG study ARAR0331 between 2006 and 2012 and the GPOH NPC protocol between 2003 and 2021 were retrospectively analyzed for the level of available plasma (P-EBV) or whole-blood EBV DNA (WB-EBV), both pre-treatment and post-induction chemotherapy. Patients were dichotomized into high and low groups based on the median pre-treatment EBV value. Results: Pre-treatment EBV DNA levels from 102 patients (50 and 23 P-EBV DNA from the COG and GPOH, respectively, and 29 WB-EBV from GPOH) and post-induction EBV DNA levels from 61 patients (31 and 12 P-EBV DNA from the COG and GPOH, respectively, and 18 WB-EBV DNA from GPOH) were evaluated. Patient characteristics, including age and disease stage, were not associated with high and low P-EBV values in any cohort. Disease stage correlated with high EBV levels in the WB-EBV GPOH cohort (p = 0.014). Pre-treatment P-EBV and WB-EBV levels showed no significant association with 5-year event-free survival (EFS: COG p = 0.65, GPOH P-EBV: p = 0.08, GPOH WB-EBV: p = 0.75) or 5-year overall survival (OS: COG p = 0.90, GPOH P-EBV p = 0.17, GPOH WB-EBV p = 0.19). Conclusions: Our study could not establish a significant correlation between outcome and pre-treatment EBV DNA in pediatric NPC patients from non-endemic areas.